LitAlert ~~ GeneLit.com

    • Differences in cancer patients’ and clinicians’ preferences for disclosure of uncertain genomic tumor testing results.
    • Fenton AT, Anderson EC, Scharnetzki E, Reed K, Edelman E, Antov A, Rueter J, Han PKJ, MCGI Working Group.
    • Patient Educ Couns. 2020 Jul 15:S0738-3991(20)303839. doi: 10.1016/j.pec.2020.07.010. Epub ahead of print.
    • Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system
    • McCuaig JM, Care M, Ferguson SE, Kim RH, Stockley TL, Metcalfe KA.
    • Gynecol Oncol. 2020 Jul 14. pii: S0090-8258(20)32333-7. doi: 10.1016/j.ygyno.2020.06.507. [Epub ahead of print]
    • PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: A meta-analysis.
    • Lin Q, Liu W, Xu S, Shang H, Li J, Guo Y, Tong J.
    • BJOG. 2020 Jul 12. doi: 10.1111/1471-0528.16411. Epub ahead of print.
    • Meta-Analysis
    • Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study.
    • Majic A, Miše BP, Matkovic V, Lovasic IB, Katic K, Canjko I, Frobe A, Bajic Z, Vrdoljak E.
    • J Oncol. 2020 Jun 20;2020:6423936. doi: 10.1155/2020/6423936.